Drug Profile

Avanbulin - Basilea Pharmaceutica

Alternative Names: BAL 27862

Latest Information Update: 24 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Basilea Pharmaceutica
Class Antineoplastics; Imidazoles; Oxadiazoles; Small molecules
Mechanism of Action Apoprotein stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

24 May 2022 Preclinical development in Cancer is ongoing in Switzerland (unspecified route )
24 May 2022 Preclinical trials in Cancer in Switzerland (unspecified route)
08 Apr 2022 Pharmacodynamics data from preclinical trials in Cancer presented at the 113th Annual Meeting of American Association for Cancer Research (AACR-2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com